Press Release

A USD 175 Million India Preclinical Research Market to Flourish at a CAGR of Around 11.5% During 2025-30

The India Preclinical Research Market size was valued at around USD 175 million in 2024 and is projected to reach USD 300 million by 2030. Along with this, the market is projected to grow at a CAGR of around 11.5% during the forecast period (2025-30), cites MarkNtel Advisors in the recent research report. The market's expansion is ascribed to several factors including the sizeable patient base, rising demand for innovative drug development, encouraging government policies, low trial costs, technological developments, and growing outsourcing trends of clinical trials in the R&D domain globally. Due to the large number of patients suffering from autoimmune, immunology, cardiovascular, infectious, rare, oncology, & respiratory diseases and central nervous system (CNS) disorders in India, the requirement for preclinical research and testing grows drastically.

Moreover, multinational pharmaceutical companies seeking to optimize their R&D expenditures find India to be a desirable option due to its affordable and high-quality preclinical research services as compared to other markets in the US and Europe. India also offers high-class research facilities and equipment with innovative research techniques available at low operational cost enhancing its competitiveness in the global market. The highly skilled human resources including scientists, researchers, and technicians trained in conducting complex preclinical studies further boosts the market growth in India. With multiple schemes, policies, and regulatory support from the government, the growth of the preclinical research market becomes impeccable. Moreover, India is becoming the hub for outsourcing research and development (R&D) activities worldwide for various industries like pharmaceuticals, biotechnology, medical devices, and agrochemicals leveraging CROs for preclinical research studies.

Despite numerous growth opportunities, some restraining factors can adversely affect the market size & volume. Complex compliance requirements are essential to function in the industry which pose challenges for CROs working with international clients. Also, the approval procedure for these regulations is time-consuming and would drastically impact project timelines. Moreover, the data integrity issue is prominent between various global pharmaceutical sponsor companies and their CROs. Furthermore, patient enrollment and retention is difficult due to the negative perception of human clinical trials in India However, innovations in drug discovery and technological advancements will continue to transform Indian preclinical research, further estates the research report, “India Preclinical Research Market Analysis, 2025.”

Segmentation Analysis

The Patient-Derived Organoid (PDO) Model Holds the Largest Market Share

Based on model type, the market is further bifurcated into the Patient-Derived Organoid (PDO) Model and Patient-Derived Xenograft (PDX) Model. Out of them, the Patient-Derived Organoid (PDO) Model leads the market with more than 50% of the market share. PDO models are becoming increasingly crucial in preclinical research as they provide a closer stimulation of human biology than animal models. This allows more accurate preclinical testing and helps in creating drugs for highly complex diseases like cancer. It also offers versatile tools which help in the cryopreservation of the specimens. In India, they find their major application in personalized medicine. This is because they work on patient-specific tissues for testing drug efficacy ultimately helping in tailored healthcare.

South India Leads the Indian Preclinical Research Industry

South India leads in Preclinical Research. It holds more than 35% of the total market share. This is due to the presence of well-established centers for the research and development of biotech and pharmaceuticals in cities like Hyderabad, Bengaluru, and Chennai. The region has become a hotspot for preclinical services with the presence of leading companies like Syngene International and GVK Biosciences. Moreover, with numerous universities and research institutions that produce talent specialized in life sciences, the region is filled with a large number of highly skilled professionals that further push market growth & expansion. The government support in the region towards the growth and development of biotech and pharma sectors has laid an impeccable foundation for research facilities to flourish.

Competitive Landscape

With strategic initiatives such as mergers, collaborations, and acquisitions, the leading market companies, including Syngene International Limited, Dabur Research, JSS Medical Research, Jubilant Biosys Ltd., Sugen Life Sciences, Eurofins Advinus, GVRP, Veeda Clinical Research Limited, Axis Clinicals, Syneos Health, Ethicare-cro, Liveon Biolabs Pvt. Ltd., IQVIA Inc., Bioneeds, TheraIndx Lifesciences Pvt. Ltd., Abiogenesis Clinpharm, Accutest Global, Asiatic Clinical Research, Bio Reliance Corporation, Cliniminds, Hi Tech Bio Laboratories, GVK Biosciences, and others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report                                  

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the country?
4. How has the industry been evolving in terms of geography & service adoption?
5. How has the competition been shaping up across various regions?
6. How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?